Home Web Research

Web Research

Claude View

Web Research: What the Internet Knows About Genpact

The Bottom Line from the Web

The web paints a far darker near-term picture than the filings alone suggest — but also delivers one large, unambiguously bullish anchor. Genpact traded at a 52-week low of $33.92 on April 10, 2026 — days before this report — and sits near $36.63 versus a May-2025 high of $50.41, a drawdown of roughly 27% in under a year. Susquehanna cut the price target from $50 to $42 right after the Q4-2025 print, and a second analyst downgrade in February 2026 drove the stock to new lows. Meanwhile, Capgemini closed its $3.3B acquisition of WNS at $76.50/share on October 17, 2025 — an unambiguous transaction-anchored peer comp that the market has not yet applied to Genpact — and Nalanda Capital added roughly 1 million shares in February 2026 into the weakness, raising its stake to ~8.07%.

What Matters Most

The eleven findings below are ranked by how much they should move an investor's view of the stock today.

1. Capgemini/WNS deal closed Oct 17, 2025 at $3.3B — sets the BPM transaction multiple

Capgemini completed its $3.3B cash acquisition of WNS at $76.50/share on October 17, 2025, a 28% premium to the 90-day average and 17% to WNS's pre-announcement close (capgemini.com, everestgrp.com, reuters.com). This is the single most important peer datapoint on the web: it confirms that a strategic acquirer will pay ~2.9x EV/Sales for a pure-play BPM franchise pivoting to agentic AI. Against Genpact's current ~1.4x EV/Sales (implied by $6.2B market cap + ~$1.2B net debt on $5.1B revenue), the comp suggests the stock trades at a ~50% discount to the most recent strategic transaction in the space.

2. Stock at 52-week low despite raised guidance — the market is pricing disbelief

Shares closed $36.63 on April 16, 2026 (CNBC), after hitting a 52-week low of $33.92 on April 10, 2026 — yet Q2-2025 revenue beat consensus (+6.6% YoY), ATS grew +17.3%, and management raised FY25 revenue guidance to +5% at midpoint (media.genpact.com, 2025-08-07). Q3-2025 then delivered another beat with ATS up 20% YoY (prnewswire.com, 2025-11-06). Forward P/E has compressed to 9.1x (CNBC) vs. the market's high-teens and EXLS's 30x+. This is the single most important contradiction between filings and tape — the AI-pivot story is not earning a multiple.

3. Nalanda Capital added ~1M shares in Feb-2026 — anchor investor doubling down

Pulak Prasad's Nalanda Capital filed its most recent 13F on February 18, 2026 (period ending Dec 31, 2025) showing Genpact as its top US holding, and The Motley Fool confirmed on Feb 20, 2026 that the fund added roughly a million shares into the post-earnings sell-off (fool.com, 2026-02-20; whalewisdom). Nalanda is known for concentrated, long-duration, "buy companies you don't need to sell" positions — the fund manages ~$5B for US endowments and European family offices and holds only two US positions (Genpact and WNS). The WNS position is now realized cash (Capgemini deal) — freeing capital that could be redeployed into G.

4. Susquehanna cut price target $50 → $42 on Feb 6, 2026 — framing the re-rating

Within hours of the Q4-2025 earnings release on Feb 6, 2026, Susquehanna reduced its G price target to $42 from $50 (TipRanks via CNBC). A separate analyst downgrade on Feb 11, 2026 drove the stock to fresh 52-week lows per Defense World and Markets Daily (Mizuho cut target to $49 from $51). BMO's Keith Bachman cut his target to $44 from $48, maintaining Market Perform. Baird had earlier cut $56 → $50 on May 10, 2025. The proximate bear thesis per TipRanks ("conflicting sentiments on technology companies," Feb 9, 2026): sell-side views Genpact's AI pivot as slower and more capital-intensive than EXLS's. Consensus 12-month target remains ~$51–$52 (indmoney.com, marketscreener).

5. Executive team expansion signals GenpactNext is real (not just a rebrand)

On Dec 10, 2025, Genpact announced three senior appointments explicitly to "fuel integration of Advanced Technology Solutions": Vijay Vijayasankar (leading Industry + GenpactNext delivery), Wayne Busch (Head of NextGen Enterprises P/L), and Sydney Brie Schaub (Chief Legal Officer) — prnewswire.com. CEO BK Kalra framed it: "We are intentionally disrupting ourselves, building a new Genpact and defining the future of Agentic Operations." Adding a dedicated "NextGen Enterprises" P/L leader answers the Historian's question about whether GenpactNext is a product change or a marketing rebrand — the org-chart move says the former.

6. Board refresh — Cisco EVP Thimaya Subaiya added July 2025

Subaiya joined the board on July 31, 2025 from Cisco, where he runs a $13B services P/L as EVP of Operations; prior career at Salesforce and Oracle (prnewswire.com). Chairman Jim Madden framed the appointment as "supporting the leadership team in advancing the GenpactNext framework." This is a meaningful governance signal — the board is skewing toward software/services-transformation expertise rather than traditional BPM.

7. XponentL Data acquisition closed June 5, 2025 — capability fill, not scale

Genpact acquired XponentL Data (Databricks partner, AI/data products, PA-headquartered) on June 5, 2025 — financial terms were not disclosed in the press release (prnewswire.com). Quant's research notes that the deal dragged ROIC from 28.8% to 17.5%, pointing to a ~$160M price tag. CEO Tom Johnstone stays on to run the XponentL business inside Genpact. No web-sourced segment contribution has been disclosed — the capital-return question remains open.

8. Bookings in 2025 dipped to $5.5B from $5.7B — no explicit explanation

FY2024 posted record new bookings of $5.7B, +15% YoY (prnewswire.com, 2025-02-06). FY2025 bookings were publicly cited as "over $5.5B" (businesswire.com, 2026-02-05), down ~3.5% YoY despite record backlog commentary. Notably, ATS represented more than a third of FY25 bookings. The Q4-2025 press release leaned entirely on "record backlog" language rather than the bookings number — the silence on the decline is itself a signal. Management claims backlog is at record levels, but no detailed bridge was provided.

9. November 2025 post-earnings gain of ~16% shows earnings still move the stock both ways

A Nov 7, 2025 Motley Fool piece titled "Why Genpact Stock Raced Nearly 16% Higher Today" documents the Q3-2025 beat reaction (fool.com). Combined with the subsequent Feb 2026 downgrades, this demonstrates a binary, event-driven market — the stock is not being valued as a stable compounder. Expectations reset sharply on every print, which creates both risk and asymmetric set-ups around upcoming earnings (next date: May 7, 2026 per CNBC).

10. Dividend raised for 8 consecutive years — capital return story intact

Annual dividend is $0.75/share, yielding 2.05%, with 8 consecutive years of growth and an 11.48% 1-year growth rate; payout ratio a conservative 21%. Q2-2025 alone returned $54.8M in dividends + $30M in buybacks; Q1-2025 repurchased 1.2M shares at an average $52.17 — above today's $36.63 price, meaning recent buybacks have been poorly timed (media.genpact.com, 2025-05-07).

11. ISS Governance QualityScore = 1 (best decile)

ISS's overall QualityScore for Genpact as of February 1, 2026 is 1 (Audit 1; Board 1; Shareholder Rights 3; Compensation 2) — simplywall.st. No proxy-advisor opposition coverage surfaced for Kalra's 2025 compensation package or any off-cycle retention grant. No SEC investigation, restatement, or material-weakness coverage appeared in the web pull.

Recent News Timeline
No Results

What the Specialists Asked

The four specialists submitted targeted queries with "high" priority answers anchoring the tabs below.

Insider Spotlight

Web research on individual insiders was consistent with a clean governance profile — no scandals, no adverse regulatory coverage, no forced departures. Key personnel snapshot below.
No Results
No Results

Source: marketscreener.com/quote/stock/GENPACT-LIMITED-57248/company + whalewisdom 13F (filed 2026-02-18). Nalanda increased by ~1M shares in Feb 2026 per fool.com; stake now ~8.07%, #4 holder.

Industry Context

BPM/IT-Services peer framing from the web search, focused on the two datapoints that matter most for G's multiple: EXLS premium and the WNS transaction anchor.
No Results

Sources: CNBC (G TTM/fwd PE), Nasdaq/Zacks (EXLS), Capgemini/Reuters/Everest Group (WNS deal), stockanalysis.com (ACN). EV/Sales for WNS = deal price 2.9x; current G implied from $6.2B market cap + ~$1.2B net debt / $5.1B revenue.

Key industry findings from the web:

  • Strategic acquirer has set a concrete floor. Capgemini paid 2.9x EV/Sales for WNS in Oct 2025 — a 28% premium to WNS's 90-day average. Genpact trades at ~1.4x EV/Sales, implying ~100% deal-multiple upside to the most recent strategic transaction.
  • Agentic-AI displacement risk is concrete, not theoretical. CNBC's Mar 19, 2026 headline about Meta "cutting third-party vendors in favor of AI" appeared in G's own CNBC news rail. Everest Group explicitly framed the Capgemini-WNS deal as "renewed BPS positioning in an AI-first world" — confirming the structural threat driving the multiple compression.
  • Peer valuation gap is the investable thesis. G at 9.1x forward vs. EXLS >28x suggests either (a) a closing opportunity if ATS sustains >15% growth, or (b) a value-trap if agentic disintermediation accelerates faster than Genpact can pivot.
  • Capital-return discipline intact. 8 consecutive years of dividend growth (+11.5% last year, koyfin.com) and an active buyback (Q1-2025: 1.2M shares at $52.17 avg, Q2-2025: $30M). The $52.17 avg buyback price is now 30% underwater — a bad trade tactically, but a real signal of management conviction.
  • Credit is fine. Long-term debt $1.2B against $855M TTM EBITDA; Debt/Equity 61.25% (CNBC). November 2025 pricing of 4.950% Senior Notes due 2030 by Genpact UK Finco/Genpact USA (sec.gov) — credit markets remain open at tight spreads.